THE CITATION REGISTER
BPC-157 TB-500 References and Sources
Every quantitative claim on this site resolves to one of the entries below — the peer-reviewed component literature, the 2025-2026 systematic reviews, and the FDA regulatory record.
How this register is organized
This is the citation register for the Wolverine blend digest. Entries 1-6 are the peer-reviewed single-component literature for BPC-157 and TB-500 / Thymosin Beta-4. Entries 7-9 are the 2025-2026 systematic and narrative reviews that bound the evidence and the safety picture. Entries 10-12 are the FDA regulatory sources behind the Wolverine legal status and FDA 503A compounding access page.
The blend has no combination literature of its own — that absence is itself the central finding [7]. Each numbered marker across the combination rationale and synergy claim, the BPC-157 and TB-500 benefits for tendon and tissue recovery page, the dosage record, and the FAQ points back to one of these entries. The full reference list with PMIDs and DOIs is below.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
- Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
- Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. ↗
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical and 1 human; "shows promise" only from level IV-V evidence; no clinical safety data; no mention of TB-500 or combination use.) ↗
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Animal-model promise but scarce human safety data and potential for serious harm; unapproved peptides including BPC-157 and TB-500 / thymosin beta-4 operate largely outside regulatory oversight.) ↗
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. (Human data limited to three small pilot studies; considered investigational given regulatory controversy and non-regulated availability.) ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"; effective with the September 29, 2023 list update; cited safety rationale includes potential immunogenicity for certain routes and impurity/characterization complexity. Verified 2026-05-29.) ↗
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B compounding framework and bulks-list/nomination process; the prescriber-evaluation access pathway. Verified 2026-05-29.) ↗
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Published agenda lists BPC-157 and TB-500 among bulk drug substances being considered for inclusion on the 503A bulks list; a scheduled discussion of substances under evaluation, not a decision or outcome. Verified 2026-05-29.) ↗